The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-When will UK dividends bounce back to pre-pandemic levels?

Wed, 21st Oct 2020 10:11

* European stocks fall for second straight session

* Centamin shares down 20% after production update

* Construction sector dips 2.3%
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You
can share your thoughts with us at markets.research@thomsonreuters.com

WHEN WILL UK DIVIDENDS BOUNCE BACK TO PRE-PANDEMIC LEVELS? (0900 GMT)

It's anyone's guess!

Link Group says the best case scenario is a recovery to 2012-13 levels in 2021.

UK dividends have recovered a tad from the depths of last quarter but they still had the
lowest third quarter in ten years, leaving investors eager to find out how much they will wait
to see payouts levels bouncing back.

Underlying dividends, which exclude special payments, fell 45.1% to £17.7bn in Q3, according
to Link Group.

"Though by any normal standards a fall of this magnitude is terrible for investors, it is
significantly better than the 57.2% drop in the second quarter," it says.

Link Group adds that investors will likely only see dividends recovering by March 2021 and
it pencils in a best-case increase of 15% and a worst case of 6% for next year.

"The fourth quarter this year and the first quarter next are set for further sharp declines,
but from April onwards, the anniversary of the lockdown, the comparisons will start to look more
favourable and we expect to see a bounce-back begin".

(Joice Alves)

******

EUROPEAN STOCKS HEAD LOWER (0800 GMT)

European stocks dipped for the second straight day dragged down by construction, healthcare
and oil outweighing a decent batch of better-than-expected Q3 results.

The STOXX 600 is down 0.6%, with the construction sector leading the losses.

In terms of single stocks, Shares in Ericsson are up 7%, after quarterly core
earnings beat market estimates and the company says it is "more confident" in meeting its 2020
targets.

Mining company Centamin's shares fell to the bottom of the pan European index, down
18% after the company’s production update.

Shares in Iberdrola are down 0.6%, after the company issued results and announced
its U.S. unit Avangrid agreed to buy U.S. utility PNM Resources for around $4.3
billion.

(Stefano Rebaudo and Joice Alves)

*****

ON THE RADAR: IBERDROLA UNIT MERGER, AKZO NOBEL, ERICSSON (0639 GMT)

European stocks are poised to open higher, with sentiment boosted by hopes for a U.S. rescue
package and better-than-feared earnings results.

While concerns about the pandemic in Europe continue to weigh, we have a decent batch of
corporate news to cheer up investors, starting with a multi-billion cross border merger in the
renewable energy sector. Avangrid, the U.S. unit of Iberdrola, has agreed to
buy U.S. utility PNM Resources for around $4.3 billion. The merged company would have
assets worth $40 billion and generate core earnings of around $2.5 billion and net profit of
$850 million.

Akzo Nobel reports a better-than-expected 18% increase in third-quarter core
profit to 353 million euros.

Nestle stocks are up 2.7% in premarket trade after the company beats Q3 sales
expectations and raises its guidance for 2020.

Ericsson quarterly core earnings beat market estimates, helped by higher margins
and China's 5G rollout, and is "more confident" in meeting its 2020 targets.

Good news also on the vaccine front as AstraZeneca Plc's trial in the United States
is expected to resume as early as this week after the U.S. Food and Drug Administration
completed its review of a serious illness in a study participant.

But we still see pressure on the financial sector. Shares in GAM Holding are down
2.2% in premarket trade after results., while Handelsbanken reports
lower-than-expected quarterly net earnings due to restructuring costs.

Vinci expects earnings to continue falling in the second half of the year, as
weakness at its pandemic-ravaged airports business outweighs signs of a recovery in construction
and motorway traffic.

GlaxoSmithKline would move its experimental vaccine against the respiratory
syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of
testing, encouraged by mid-stage trial results.

Shares in Bilfinger are up 7.2% after press reports on possible takeover of the
company.

(Stefano Rebaudo)

*****

EUROPE CAUTIOUSLY IN THE BLACK (0528 GMT)

European stock futures are in the black along with their U.S. peers as hopes of a quick
approval of a U.S. stimulus package are propping up risk sentiment.

But investors continue to be cautious as coronavirus trajectories as well as possible new
restrictive measures are now seen as the single biggest near-term risk to the economic recovery.

Italy, Spain and Britain are considering new restrictions, including curfew in hard-hit
regions, to limit the spread of the pandemic. The latest curbs in Ireland will see GDP fall by
3.5% this year, Finance Minister Paschal Donohoe said.

(Stefano Rebaudo)

*****

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.